EMCURE PHARMACEUTICALS LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,375 INR | +0.90% |
|
0.00% | 0.00% |
| 07-10 | INDIA STOCKS-Indian shares flip to declines as Mahindra & Mahindra, banks weigh | RE |
| 07-10 | India's Emcure Pharma jumps 35% in debut trade at $223 million valuation | RE |
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net sales 1 | 47,172 | 50,486 | 60,564 | 33,872 | 31,071 | 34,977 |
| EBITDA 1 | 7,435 | 6,657 | 11,843 | 7,726 | 4,162 | 4,082 |
| EBIT 1 | 4,863 | 3,912 | 9,087 | 6,289 | 2,602 | 2,371 |
| Operating Margin | 10.31% | 7.75% | 15% | 18.57% | 8.38% | 6.78% |
| Earnings before Tax (EBT) 1 | 3,226 | 1,053 | 6,573 | 6,164 | 2,123 | 1,999 |
| Net income 1 | 1,893 | 836.1 | 3,921 | 4,468 | 1,601 | 1,608 |
| Net margin | 4.01% | 1.66% | 6.47% | 13.19% | 5.15% | 4.6% |
| EPS 2 | 10.47 | 4.620 | 21.68 | 24.71 | 8.850 | 8.890 |
| Free Cash Flow | - | 2,751 | 4,951 | 4,830 | 1,306 | 1,365 |
| FCF margin | - | 5.45% | 8.18% | 14.26% | 4.2% | 3.9% |
| FCF Conversion (EBITDA) | - | 41.32% | 41.81% | 62.53% | 31.39% | 33.44% |
| FCF Conversion (Net income) | - | 329% | 126.26% | 108.11% | 81.62% | 84.86% |
| Dividend per Share 2 | 4.500 | 2.500 | 1.000 | 1.000 | 1.000 | - |
| Announcement Date | 8/20/21 | 8/20/21 | 8/20/21 | 6/9/23 | 6/9/23 | 5/27/24 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 22,022 | 21,629 | 19,359 | 16,394 | 16,506 | 15,836 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.962 x | 3.249 x | 1.635 x | 2.122 x | 3.966 x | 3.88 x |
| Free Cash Flow | - | 2,751 | 4,951 | 4,830 | 1,306 | 1,365 |
| ROE (net income / shareholders' equity) | - | 5.19% | 19.2% | 21.9% | 9.01% | 8.52% |
| ROA (Net income/ Total Assets) | - | 4.14% | 8.87% | 7.06% | 3.64% | 3.16% |
| Assets 1 | - | 20,198 | 44,232 | 63,265 | 43,988 | 50,873 |
| Book Value Per Share 2 | 101.0 | 106.0 | 126.0 | 94.70 | 102.0 | 107.0 |
| Cash Flow per Share 2 | 5.060 | 7.120 | 25.90 | 1.710 | 6.750 | 0.6600 |
| Capex 1 | 3,268 | 1,153 | 1,254 | 1,741 | 2,717 | 2,493 |
| Capex / Sales | 6.93% | 2.28% | 2.07% | 5.14% | 8.74% | 7.13% |
| Announcement Date | 8/20/21 | 8/20/21 | 8/20/21 | 6/9/23 | 6/9/23 | 5/27/24 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 3.11B | |
| +63.05% | 856B | |
| +39.03% | 631B | |
| -4.78% | 359B | |
| +17.52% | 325B | |
| +8.43% | 297B | |
| +13.91% | 244B | |
| +5.03% | 234B | |
| +16.26% | 226B | |
| +14.63% | 177B |
- Stock Market
- Equities
- EMCURE Stock
- Financials Emcure Pharmaceuticals Limited
